+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 27 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the prognostic value of a genomic classifier called S18 and its refined version S* in women with early-stage HER2-positive breast cancer. The study focuses on whether these tools can predict event-free survival EFS and disease-free survival DFS in patients treated with trastuzumab-based therapies, with or without pertuzumab. This observational study includes women aged 18 or older with operable stage I to III HER2-positive breast cancer. The study uses data and tumor tissue samples collected from two cohorts of patients who received neoadjuvant andor adjuvant trastuzumab pertuzumab therapies. It combines clinical, pathological, and genomic information to refine and validate the prognostic capability of the S18 classifier. No investigational treatments are administered as part of this observational research. Participants provide informed consent and their clinical and genomic data are analyzed. Researchers assess outcomes such as event-free survival and disease-free survival over at least three years following systemic therapy. They also explore overall survival and pathological complete response based on the classifier values. The studys total duration includes follow-up for at least three years after treatment initiation.

Age: 18Years +All Genders
2 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of EscharEx EX-03 5% formulation compared to a placebo in the treatment of Venous Leg Ulcers VLU. This study involves adults with VLU wounds between 2 cm and 25 cm in size, with wound duration from 4 weeks to 12 months. It aims to assess how well EscharEx helps with debridement and wound bed preparation. Participants will be randomly assigned to receive either EscharEx, a sterile powder containing proteolytic enzymes enriched in bromelain, or a placebo gel without the active enzyme. The powder is mixed with sterile water to form a gel that is applied to the wound area. The study includes several periods a screening period with two visits, a daily treatment period of up to eight daily applications over two weeks, followed by weekly wound management visits for up to 12 weeks, and an optional wound closure confirmation period of up to two weeks. After wound closure, participants enter a 12-week monthly visit period to monitor wound closure durability. During the study, participants undergo clinical assessments of wound debridement and closure, including visual evaluations after each application and over the follow-up periods. Researchers will measure the incidence of complete debridement, time to wound closure, and healthy tissue development. Safety and wound healing progress are monitored throughout. The total participation can last up to 29 weeks, with regular visits to ensure detailed monitoring of wound status and treatment effects.

Age: 18Years +All GendersPhase 3
60 locations
O

Actively Recruiting

Researchers are collecting and analyzing medical records from patients with relapsed or refractory multiple myeloma RRMM who have received the treatments teclistamab or talquetamab outside of clinical trials. The study aims to describe how these treatments are used and their effects in real-world settings, focusing on patients who received these therapies during specific time periods. This observational study is sponsored by Janssen-Cilag Ltd. Participants are grouped based on when they first received teclistamab or talquetamab, covering periods up to December 2025 for teclistamab and December 2023 for talquetamab. The study does not involve administering treatments directly but collects retrospective data from medical records to describe treatment use. Data from multiple cohorts are compiled to understand outcomes following these T-cell redirector therapies. Participants medical records are reviewed to gather information on baseline characteristics, response rates, survival, and safety management over up to 40 months. Researchers track overall response rate, time to response, duration of response, minimal residual disease, overall survival, progression-free survival, and time to next treatment. The study also assesses how the treatments are managed in real-world practice, with no direct interventions or visits required from participants during this observational study.

Age: 18Years +All Genders
68 locations
P

Actively Recruiting

This research aims to evaluate the long-term safety of luspatercept in participants who have previously taken part in other luspatercept clinical trials for conditions such as Myelodysplastic Syndromes MDS, Beta-thalassemia, and Myeloproliferative Neoplasm-associated Myelofibrosis. It is a Phase 3b, open-label, single-arm rollover study designed to continue monitoring participants who tolerated previous luspatercept treatment and may benefit from ongoing therapy, as well as those in post-treatment follow-up phases. Participants transitioning from prior luspatercept studies will enter a Transition Phase defined by an enrollment visit. Those continuing treatment will receive luspatercept injections subcutaneously at the same dose and schedule as their parent trial, administered by study staff at clinical sites. The study includes a Treatment Phase for ongoing luspatercept administration and a Follow-up Phase comprising a 42-day safety follow-up after the last dose and a long-term post-treatment follow-up phase lasting at least 5 years to monitor overall survival and progression to malignancies. Throughout the study, participants will be regularly assessed for adverse events, progression to high-risk MDS or AML, and development of other malignancies or treatment-related masses. Safety parameters are evaluated during the 42-day follow-up, while long-term survival and disease progression are monitored every six months for at least five years. The study will conclude when all participants have completed five years of combined treatment and follow-up.

Age: 18Years +All GendersPhase 3
143 locations
P

Actively Recruiting

Triple-negative breast cancer TNBC is a very aggressive and deadly form of breast cancer with limited effective treatments available. Researchers are evaluating a combination of the immune therapy drug atezolizumab with chemotherapy drugs cyclophosphamide and vinorelbine. This phase II trial aims to measure the overall response rate of this combination in patients with advanced or metastatic TNBC who have previously been treated with anti-PD-1 or anti-PD-L1 therapies. Participants will receive atezolizumab intravenously at 840 mg on days 1 and 15 of each 28-day cycle. Cyclophosphamide will be given intravenously at 300 mgm2 on days 1, 8, 15, and 21, while vinorelbine will be taken orally at 30 mg on days 1, 3, and 5 weekly within each cycle. This treatment will continue as first-line therapy for metastatic TNBC. The study will also assess secondary outcomes such as duration of response, progression-free survival, overall survival, and safety of the treatment. During the trial, participants will undergo regular assessments for tumor response using RECIST 1.1 criteria, organ function tests, and performance status evaluations. Researchers will monitor the overall response rate over 30 months, along with progression-free and overall survival. Safety and tolerability will be closely followed. The total participation duration depends on treatment response and survival, with ongoing monitoring throughout the study period.

Age: 18Years +All GendersPhase 2
5 locations
S

Actively Recruiting

Researchers are evaluating the use of BIOTRONIK dual-chamber pacemakers that combine left bundle branch area pacing LBBAP with Closed Loop Stimulation CLS in patients who have sinus node dysfunction SND and atrioventricular AV conduction disorders. This observational study aims to understand how this combined pacing method works in everyday clinical practice and whether it can help reduce atrial fibrillation detected by the device over 24 months. The goal is to gather real-world evidence to optimize pacemaker programming and improve patient outcomes. Participants receive permanent dual-chamber pacemakers with a ventricular lead placed in the left bundle branch area, activating the CLS rate-responsive algorithm. The study focuses on patients implanted with these devices who have no prior history of atrial fibrillation. The study follows about 150 patients for 24 months after implantation, collecting data on device-detected atrial fibrillation episodes, heart rate patterns, and pacing behavior. This is a prospective observational submodule of the BIOSTREAM.CSP registry without a control group. During the study, researchers monitor device-recorded atrial fibrillation incidence and burden from CLS activation up to 24 months. They also analyze heart rate histograms at one and two years after implantation. Patients are enrolled in the BIOSTREAM.CSP registry and are followed through routine clinical care with data collected on pacing rates and arrhythmia episodes. The study aims to provide insights into the clinical performance of CLS combined with LBBAP to inform decisions on pacemaker programming and reduce atrial arrhythmias.

Age: 18Years - 18YearsAll Genders
12 locations
O

Actively Recruiting

The registry is designed to evaluate the outcomes, performance, and safety of BIOTRONIK devices used in conduction system pacing CSP through long-term data collected in real-world clinical settings. It includes patients who receive these devices as part of routine care to better understand their use and effects over time. The study is observational and collects data from unselected patients without intervention by the researchers. Participants receive BIOTRONIK devices for conduction system pacing, including the implantation of the Solia CSP S pacing lead for left bundle branch area pacing LBBAP. The study includes patients who are newly implanted, recently implanted but not yet discharged, or transitioning from a related study. The registry tracks device performance and safety over an average of 4 years through annual assessments. During the study, participants will undergo evaluations including the rate of device-related serious adverse events, success of acute implantation, capture type at implantation, long-term maintenance of pacing, and electrical parameters such as pacing threshold, sensing amplitude, and impedance. Participants will use the BIOTRONIK Home Monitoring system with the CardioMessenger device to support follow-up, which requires their willingness and ability to comply with study visits and monitoring over time.

Age: 18Years +All Genders
46 locations
S

Actively Recruiting

Researchers are studying patients with hormone receptor-positive, HER2-negative early breast cancer HRHER2- EBC who are at high risk of their cancer returning. This observational study includes both past and future phases to assess the clinical and pathological features, treatment choices, and outcomes of patients treated with CDK46 inhibitors ribociclib or abemaciclib combined with endocrine therapy in the adjuvant setting. The study also focuses on patients whose cancer returned during or within 12 months after finishing this adjuvant treatment. Participants are those who have started or are starting adjuvant treatment with ribociclib or abemaciclib along with endocrine therapy since January 1, 2021. This study does not involve assigning treatments but observes patients receiving these therapies in real-world settings. It gathers data on treatment patterns, recurrence, and clinical outcomes without altering patient care. During the study, researchers will collect and analyze data on patient health, tumor characteristics, and treatment responses. They will track invasive disease-free survival over 3 years as the main outcome, along with distant relapse-free survival, progression-free survival, and overall survival up to 5 years. Participants will provide consent for their data to be used, and their health status will be monitored through routine medical records and follow-ups. The study is expected to continue until August 2030.

Age: 18Years +All Genders
18 locations
E

Actively Recruiting

Researchers are investigating how emotional distress ED affects treatment outcomes in patients with metastatic breast cancer mBC who are receiving first-line therapies. This study focuses on the impact of baseline emotional distress on the effectiveness of various treatments according to breast cancer subtypes. Emotional distress is common among breast cancer patients and has been linked to poorer treatment adherence and quality of life, but its role in metastatic breast cancer treatment success is not well understood. Participants will be grouped based on their breast cancer subtype and receive standard first-line treatments accordingly triple-negative PD-L1 positive patients receive chemotherapy with immune checkpoint inhibitors, triple-negative PD-L1 negative patients receive chemotherapy alone, HR-positiveHER2-negative patients receive a CDK46 inhibitor plus endocrine therapy, and HER2-positive patients receive chemotherapy combined with trastuzumab and pertuzumab. Emotional distress and quality of life will be assessed through questionnaires at baseline and during treatment. During the study, patients will complete specific questionnaires to measure emotional distress, quality of life, and fear of cancer progression. Researchers will monitor progression-free survival and objective response rates over two years, comparing outcomes based on emotional distress levels at the start and early in treatment. Quality of life and psychological factors will also be evaluated over three months. All participants must provide informed consent and meet eligibility criteria before joining.

Age: 18Years +All Genders
37 locations
S

Actively Recruiting

Researchers are studying patients with early breast cancer, focusing on those with HER2-positive and Triple Negative tumors who have received neoadjuvant treatment in the past five years. The study aims to understand the percentage of such patients among all who underwent neoadjuvant treatment, along with analyzing treatment choices, tumor characteristics, responses to therapy, surgical procedures, and survival outcomes based on molecular subtypes and initial cancer staging. This observational study reviews clinical data collected from multiple oncology centers in Italy. It examines neoadjuvant treatments given before surgery, the radiological responses assessed by breast MRI, ultrasound, or mammography, and the surgical methods used on the breast and axilla. The study also looks at adjuvant therapies after surgery and tracks changes in eligibility criteria for neoadjuvant treatments over the last five years. Participants medical records will be evaluated to capture information on tumor pathology, treatment responses, and survival rates including disease-free and overall survival. The primary measurement is the percentage of HER2-positive and Triple Negative patients treated neoadjuvantly during the defined period. Secondary analyses include treatment patterns, pathological and radiological responses, surgical details, and correlations between complete pathological response and survival outcomes. The study spans five years of retrospective data and is led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Age: 18Years +All Genders
29 locations

1-10 of 27

1